Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis

Sherise C. Rogers; Christine A. Garcia; Shenhong Wu

doi:10.1080/07357907.2017.1344697

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis

Sherise C. Rogers
, Christine A. Garcia
, Shenhong Wu

Medical Oncology

Stony Brook University
University of Pittsburgh

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus to placebo and reported discontinuation due to AE with everolimus (related and unrelated to everolimus) and placebo (unrelated to everolimus). Incidence of discontinuation with everolimus due to AE and placebo was 12.3% and 4.7% respectively. Relative risk of everolimus discontinuation due to related AE was 2.60. Risk of discontinuation varied by tumor type, however everolimus dose or concomitant chemotherapy was not significant.

Original language	English
Pages (from-to)	552-561
Number of pages	10
Journal	Cancer Investigation
Volume	35
Issue number	8
DOIs	https://doi.org/10.1080/07357907.2017.1344697
State	Published - Sep 14 2017

Keywords

Cancer
Discontinuation
Everolimus

Access to Document

10.1080/07357907.2017.1344697

Cite this

@article{00349b51a846407f9574091c6da62218,

title = "Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis",

abstract = "A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus to placebo and reported discontinuation due to AE with everolimus (related and unrelated to everolimus) and placebo (unrelated to everolimus). Incidence of discontinuation with everolimus due to AE and placebo was 12.3\% and 4.7\% respectively. Relative risk of everolimus discontinuation due to related AE was 2.60. Risk of discontinuation varied by tumor type, however everolimus dose or concomitant chemotherapy was not significant.",

keywords = "Cancer, Discontinuation, Everolimus",

author = "Rogers, \{Sherise C.\} and Garcia, \{Christine A.\} and Shenhong Wu",

note = "Publisher Copyright: {\textcopyright} 2017 Taylor \& Francis Group, LLC.",

year = "2017",

month = sep,

day = "14",

doi = "10.1080/07357907.2017.1344697",

language = "English",

volume = "35",

pages = "552--561",

journal = "Cancer Investigation",

issn = "0735-7907",

number = "8",

}

TY - JOUR

T1 - Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients

T2 - A Meta-Analysis

AU - Rogers, Sherise C.

AU - Garcia, Christine A.

AU - Wu, Shenhong

PY - 2017/9/14

Y1 - 2017/9/14

N2 - A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus to placebo and reported discontinuation due to AE with everolimus (related and unrelated to everolimus) and placebo (unrelated to everolimus). Incidence of discontinuation with everolimus due to AE and placebo was 12.3% and 4.7% respectively. Relative risk of everolimus discontinuation due to related AE was 2.60. Risk of discontinuation varied by tumor type, however everolimus dose or concomitant chemotherapy was not significant.

AB - A meta-analysis of randomized controlled trials (RCTs) was performed to examine the risk of everolimus discontinuation due to related and unrelated adverse events (AE) in cancer patients. Fifteen RCTs were analyzed that compared everolimus to placebo and reported discontinuation due to AE with everolimus (related and unrelated to everolimus) and placebo (unrelated to everolimus). Incidence of discontinuation with everolimus due to AE and placebo was 12.3% and 4.7% respectively. Relative risk of everolimus discontinuation due to related AE was 2.60. Risk of discontinuation varied by tumor type, however everolimus dose or concomitant chemotherapy was not significant.

KW - Cancer

KW - Discontinuation

KW - Everolimus

UR - https://www.scopus.com/pages/publications/85030466549

U2 - 10.1080/07357907.2017.1344697

DO - 10.1080/07357907.2017.1344697

M3 - Review article

C2 - 28799817

AN - SCOPUS:85030466549

SN - 0735-7907

VL - 35

SP - 552

EP - 561

JO - Cancer Investigation

JF - Cancer Investigation

IS - 8

ER -

Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this